Literature DB >> 28592745

Clinicopathological features of cryptococcal lymphadenitis and a review of literature.

Keisuke Kawamoto1,2, Hiroaki Miyoshi2, Takaharu Suzuki1, Reiji Muto2, Kyohei Yamada2, Eriko Yanagida2, Mayuko Koshino2, Yuya Sasaki2, Jun Takizawa1, Hirohito Sone1, Yasuo Sugita2, Masao Seto2, Koichi Ohshima2.   

Abstract

Cryptococcosis is an invasive fungal infection in immunocompromised patients. The clinicopathological characteristics of cryptococcal lymphadenitis are not well known. We analyzed three cases of cryptococcal lymphadenitis and compared their characteristics with those in previous reports. Two patients were human immunodeficiency virus (HIV) carriers, and one patient was a human T-cell leukemia virus type-1 (HTLV-1) carrier. The age of the HTLV-1 carrier with cryptococcosis was much higher than that of the HIV-1 carriers. CD4-positive cell counts in peripheral blood were 5.8/μL (Case 1) and 79.9/μL (Case 2) in the HIV carriers and 3285/μL in the HTLV-1 carrier (Case 3). According to flow cytometric analysis of the lymph nodes of Cases 1, 2, and 3, 50.0%, 87.1%, and 85.9%, respectively, of the T-cells were CD3; 9.8%, 16.3%, and 75.8%, respectively, were CD4; and 35.5%, 77.3%, and 10.2%, respectively, were CD8. Cryptococcus neoformans was detected in tissue culture in all patients. Although gelatinous lesions and numerous fungal cocci were observed in the two HIV patients, the granuloma formation was small. Gelatinous formation and granuloma formation were observed in the HTLV-1 carrier. Necrosis was observed in all cases. In previous reports, granuloma formation, epithelioid cells, and necrotic lesions were observed in most cases. Most of the patients were also immunosuppressed. However, no HTLV-1 carrier was detected. In conclusion, lymphadenopathy in a HTLV-1 carrier may suggest the presence of cryptococcal lymphadenitis. The frequency of cryptococcosis in HTVL-1 carriers may increase with increase in the long-term survival rate of HTLV-1 carriers.

Entities:  

Keywords:  Cryptococcal lymphadenitis; Cryptococcosis; HIV; HTLV-1; Immunocompromised

Mesh:

Substances:

Year:  2017        PMID: 28592745      PMCID: PMC6144269          DOI: 10.3960/jslrt.17011

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  36 in total

1.  Incidence and spectrum of AIDS-defining illnesses among persons treated with antiretroviral drugs.

Authors:  S H Michaels; R Clark; P Kissinger
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Cryptococcal lymphadenitis diagnosed by FNAC in a HIV positive individual.

Authors:  B R J Shravanakumar; K R Iyengar; Y Parasappa; R Ramprakash
Journal:  J Postgrad Med       Date:  2003 Oct-Dec       Impact factor: 1.476

3.  Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases.

Authors:  R D BAKER; R K HAUGEN
Journal:  Am J Clin Pathol       Date:  1955-01       Impact factor: 2.493

4.  Cryptococcal lymphadenitis diagnosed by fine-needle aspiration biopsy.

Authors:  Karen S Gustafson; Leonard Feldman
Journal:  Diagn Cytopathol       Date:  2007-02       Impact factor: 1.582

5.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

6.  Intraabdominal cryptococcal lymphadenitis in a patient with systemic lupus erythematosus.

Authors:  Sang-Hyon Kim; Sung-Dong Kim; Hae-Rim Kim; Chong-Hyeon Yoon; Sang-Heon Lee; Ho-Youn Kim; Sung-Hwan Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

7.  Bone marrow cryptococcal infection in the acquired immunodeficiency syndrome.

Authors:  L Pantanowitz; T Omar; H Sonnendecker; A S Karstaedt
Journal:  J Infect       Date:  2000-07       Impact factor: 6.072

Review 8.  Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.

Authors:  L W Chang; W T Phipps; G E Kennedy; G W Rutherford
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

9.  A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency.

Authors:  P Chetchotisakd; S Sungkanuparph; B Thinkhamrop; P Mootsikapun; P Boonyaprawit
Journal:  HIV Med       Date:  2004-05       Impact factor: 3.180

10.  CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract.

Authors:  J O Hill
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Dormancy in Cryptococcus neoformans: 60 years of accumulating evidence.

Authors:  Alexandre Alanio
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Multifocal cryptococcal disease in an HIV-infected patient: from diagnostic pursuit to management peculiarities.

Authors:  Isabel M Eira; Filipa S Pinho; Cindy Tribuna; Cristina Ângela
Journal:  BMJ Case Rep       Date:  2020-01-13

3.  Axillary lymphadenopathy in a liver transplant recipient: Initial manifestation of disseminated cryptococcosis.

Authors:  Vikram Saini; Lame Balikani; Janice Ahn; Zaw Min; Nitin Bhanot
Journal:  IDCases       Date:  2022-02-01

Review 4.  HTLV-1 and Co-infections.

Authors:  Carolina Rosadas; Graham P Taylor
Journal:  Front Med (Lausanne)       Date:  2022-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.